ArticleScience translational medicine2020
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Abstract read
In one paragraph
Article in Science translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 653 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
653citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
653 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Treatment of Non-severe COVID-19 with Molnupiravir: A Systematic Review with Meta-analysis and Trial Sequential Analysis of the Evidence from Randomized Controlled Trials.Clinical drug investigation · 2026Pooled it
- Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomized controlled trials.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2023Pooled it
- Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis.The Journal of antimicrobial chemotherapy · 2023Pooled it
- Exercise-Based Rehabilitation in Severe COVID-19 Survivors with Long COVID: A Randomized Controlled Pilot Study.Medical sciences (Basel, Switzerland) · 2026Trial
- Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.The Lancet. Infectious diseases · 2025Trial
- A Viroimmunologic Model to Characterize the Antiviral Effect of Molnupiravir in Outpatients Infected With SARS-CoV-2: Implication for Treatment Duration.The Journal of infectious diseases · 2025Trial
- Comparison of Molnupiravir Exposure-Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID-19.Clinical and translational science · 2025Trial
- Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT).Microbiology spectrum · 2024Trial
- Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals.CPT: pharmacometrics & systems pharmacology · 2023Trial
- Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants.Clinical and translational science · 2023Trial
- The nucleoside analog CMX521 inhibits coronavirus RNA-dependent RNA polymerase via a two-pronged mechanism.The Journal of biological chemistry · 2026Article
- Sustainable Biocatalytic Cascades: A Versatile Tool in the Synthesis of Natural Products With Therapeutic Potential.Chembiochem : a European journal of chemical biology · 2026Review
- Effectiveness of the Approved Nirmatrelvir/Ritonavir and Molnupiravir Regimens for Treatment of Mild/Moderate Laboratory-Confirmed SARS-CoV-2 Infection in Patients Aged 18-64 Years in Hong Kong: A Population-Based Cohort Study.Clinical drug investigation · 2026Article
- Multi-antigen coronavirus vaccine induces potent and durable cross-protection against multiple SARS-CoV-2 variants.NPJ vaccines · 2026Article
- Substrate and target selectivity of 4'-fluoroadenosine against viral and host polymerases.The Journal of biological chemistry · 2026Article
- The nucleoside analog CMX521 inhibits coronavirus RNA-dependent RNA polymerase via a two-pronged mechanism.bioRxiv : the preprint server for biology · 2026Article
- Addressing the zoonotic threat of merbecoviruses.Nature microbiology · 2026Review
- Copy-back RNA synthesis by coronavirus polymerase requires helicase activity and is stimulated by remdesivir and molnupiravir.Science advances · 2026Article
- The seven human coronavirus main proteases exhibit differential modulation of NF-κB suppression via TAB1 cleavage.Communications biology · 2026Article
593 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Timothy P SheahanDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. sheahan@email.unc.edu rbaric@email.unc.edu.ORCID 0000-0001-9181-2183
Amy C SimsDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-0178-4225
Shuntai ZhouLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-8353-386X
Rachel L GrahamDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-3143-6515
Andrea J PruijssersDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0001-7910-626X
Maria L AgostiniDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Sarah R LeistDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-4989-5381
Alexandra SchäferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-4760-4923
Kenneth H DinnonDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-8942-1551
Laura J StevensDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0003-4386-6958
James D ChappellDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Xiaotao LuDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0001-9935-1713
Tia M HughesDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0001-5765-3406
Amelia S GeorgeDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0001-6919-2256
Collin S HillLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0003-3968-1862
Stephanie A MontgomeryDepartment of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.ORCID 0000-0001-8012-5302
Ariane J BrownDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Gregory R BluemlingEmory Institute of Drug Development (EIDD), Emory University, Atlanta, GA 30322, USA.ORCID 0000-0001-9138-7578
Michael G NatchusEmory Institute of Drug Development (EIDD), Emory University, Atlanta, GA 30322, USA.
Manohar SaindaneEmory Institute of Drug Development (EIDD), Emory University, Atlanta, GA 30322, USA.
Alexander A KolykhalovEmory Institute of Drug Development (EIDD), Emory University, Atlanta, GA 30322, USA.
George PainterEmory Institute of Drug Development (EIDD), Emory University, Atlanta, GA 30322, USA.ORCID 0000-0002-9803-8095
Jennifer HarcourtDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0003-3271-4174
Azaibi TaminDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.ORCID 0000-0001-9726-8940
Natalie J ThornburgDivision of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Ronald SwanstromLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0001-7777-0773
Mark R DenisonDepartment of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA.ORCID 0000-0003-2655-0900
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. sheahan@email.unc.edu rbaric@email.unc.edu.ORCID 0000-0001-6827-8701
Funding
Project 4 - Influenza - UABU19AI142759 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WHITLEY, RICHARD J. · 2019 to 2023
$37.5MScreening CoreU19AI109680 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WHITLEY, RICHARD J. · 2014 to 2018
$34.9MVector CoreP30DK065988 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Richard Charles Boucher, Martina Gentzsch · 2004 to 2026
$26.5MBroad-spectrum antiviral GS-5734 to treat MERS-CoV and related emerging CoVR01AI132178 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S, SHEAHAN, TIMOTHY PATRICK · 2017 to 2021
$7.0MDeterminants of Coronavirus Fidelity in Replication and PathogenesisR01AI108197 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BARIC, RALPH S, DENISON, MARK R · 2013 to 2022
$6.5MChemical Biology of Infectious Diseases (CBID) Training ProgramT32AI112541 · NIAID · VANDERBILT UNIVERSITY · PI Eric P Skaar · 2015 to 2026
$4.0MCoronavirus antiviral nucleoside analogs: inhibition and reduced susceptibilityF31AI133952 · NIAID · VANDERBILT UNIVERSITY · PI AGOSTINI, MARIA · 2017 to 2019
$63kNIAID NIH HHS F31 AI133952NIAID NIH HHS HHSN272201500008CNIAID NIH HHS R01 AI108197NIAID NIH HHS R01 AI132178NIAID NIH HHS T32 AI112541NIAID NIH HHS U19 AI109680NIAID NIH HHS U19 AI142759NIDDK NIH HHS P30 DK065988
Abstract
Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative agent of COVID-19. Here, we show that the ribonucleoside analog β-d-N
Indexed as
Adenosine MonophosphateAlanineAnimalsAntibiotic ProphylaxisAntiviral AgentsBetacoronavirusCell LineCoronavirus InfectionsCOVID-19CytidineDisease Models, AnimalDrug Resistance, ViralHumansHydroxylaminesLungMiceAdenosine MonophosphateAlanineAntiviral AgentsCytidineHydroxylaminesmolnupiravirN(4)-hydroxycytidineremdesivirRibonucleosidesRNA-Dependent RNA PolymeraseRNA, Viral
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.